Century Therapeutics, Inc.
IPSCFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Century Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Century Therapeutics, Inc. — 10-K filed Mar 12, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 15, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| AMERICAN CENTURY COMPANIES INC | 2026-03-31 | 58,742 | $133K | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2026-03-31 | 906,827 | $2.05M | SEC filing |
| Parametrica Management Ltd | 2026-03-31 | 27,840 | $62.9K | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 40 | $90 | SEC filing |
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 55,183 | $122K | SEC filing |
| SUPERSTRING CAPITAL MANAGEMENT LP | 2026-03-31 | 119,308 | $270K | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 230,820 | $522K | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 32,987 | $74.6K | SEC filing |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-03-31 | 77,797 | $166K | SEC filing |
| Syncona Portfolio Ltd | 2026-03-31 | 1,213,056 | $2.74M | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 145,099 | $328K | SEC filing |
| Advisors Asset Management, Inc. | 2026-03-31 | 8,313 | $18.8K | SEC filing |
| RAYMOND JAMES FINANCIAL INC | 2026-03-31 | 91,323 | $206K | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 120,232 | $272K | SEC filing |
| ACADIAN ASSET MANAGEMENT LLC | 2026-03-31 | 278,075 | Not shown | SEC filing |
| Bank of New York Mellon Corp | 2026-03-31 | 12,897 | $29.1K | SEC filing |
| Seven Fleet Capital Management LP | 2026-03-31 | 2,947,826 | $6.66M | SEC filing |
| Smartleaf Asset Management LLC | 2026-03-31 | 1 | $2 | SEC filing |
| MARSHALL WACE, LLP | 2026-03-31 | 673,584 | $1.52M | SEC filing |
| TCG Crossover Management, LLC | 2026-03-31 | 17,754,430 | $39M | SEC filing |
- Each value is checked against Century Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Century Therapeutics, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Quadrant Private Wealth Management, LLC: 15,286 shares reported 2025-12-31; 20,022 shares reported 2026-03-31.
- DAFNA Capital Management LLC: 2,793,586 shares reported 2025-12-31; 2,434,353 shares reported 2026-03-31.
- FMR LLC: 71,540 shares reported 2025-12-31; 8,779 shares reported 2026-03-31.
- Arax Advisory Partners: 99 shares reported 2025-12-31; 99 shares reported 2026-03-31.
- ADAGE CAPITAL PARTNERS GP, L.L.C.: 1,838,700 shares reported 2025-12-31; 3,789,538 shares reported 2026-03-31.
- BlackRock, Inc.: 601,866 shares reported 2025-12-31; 1,524,422 shares reported 2026-03-31.
- XTX Topco Ltd: 15,333 shares reported 2025-12-31; 22,518 shares reported 2026-03-31.
- Spruce Street Capital LP: 1,421,532 shares reported 2025-12-31; 4,059,054 shares reported 2026-03-31.
- Point72 Asset Management, L.P.: 5,961,631 shares reported 2025-12-31; 5,964,678 shares reported 2026-03-31.
- SIMPLEX TRADING, LLC: 2,397 shares reported 2025-12-31; 9,028 shares reported 2026-03-31.
- GSA CAPITAL PARTNERS LLP: 333,199 shares reported 2025-12-31; 76,836 shares reported 2026-03-31.
- SUSQUEHANNA INTERNATIONAL GROUP, LLP: 50,104 shares reported 2025-12-31; 226,687 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
36 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Century Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-11-17 · Pfeiffenberger Brent: Larger than 53 of the 57 other insider sales of Common Stock on file. SEC filing
- 2025-02-18 · Pfeiffenberger Brent: Larger than 54 of the 57 other insider sales of Common Stock on file. SEC filing
- 2024-03-06 · Farid Adrienne: Larger than 52 of the 57 other insider sales of Common Stock on file. SEC filing
- 2023-03-22 · Borges Luis: Larger than 56 of the 57 other insider sales of Common Stock on file. SEC filing
- 2023-03-21 · Borges Luis: Larger than 55 of the 57 other insider sales of Common Stock on file. SEC filing
- 2022-08-09 · Versant Venture Capital VI, L.P.: Larger than all 57 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-12 | Russotti Gregory · See Remarks | Common Stock | S — Open market or private sale | −2,584 | 2.23 | SEC filing |
| 2026-06-12 | Carr Douglas · SVP Finance & Operations | Common Stock | S — Open market or private sale | −1,654 | 2.23 | SEC filing |
| 2026-06-08 | Russotti Gregory · See Remarks | Common Stock | S — Open market or private sale | −524 | 2.11 | SEC filing |
| 2026-06-08 | Carr Douglas · SVP Finance & Operations | Common Stock | S — Open market or private sale | −249 | 2.11 | SEC filing |
| 2026-05-04 | Carr Douglas · SVP Finance & Operations | Common Stock | S — Open market or private sale | −264 | 2.34 | SEC filing |
| 2026-03-12 | Carr Douglas · SVP Finance & Operations | Common Stock | S — Open market or private sale | −7,043 | 2.55 | SEC filing |
| 2026-03-12 | Russotti Gregory · See Remarks | Common Stock | S — Open market or private sale | −10,076 | 2.55 | SEC filing |
| 2026-03-09 | Carr Douglas · SVP Finance & Operations | Common Stock | S — Open market or private sale | −247 | 2.54 | SEC filing |
Showing 8 of 17 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-11 | Blackwell Kimberly · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +74,000 | SEC filing |
| 2026-06-11 | Quimi Daphne · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +74,000 | SEC filing |
| 2026-06-11 | Murphy Martin Patrick · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +74,000 | SEC filing |
| 2026-06-11 | Lee Han Myung · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +74,000 | SEC filing |
| 2026-06-11 | Riva Alessandro · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +74,000 | SEC filing |
| 2026-06-11 | Cowan Chad · Chief Scientific Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −358 | SEC filing |
| 2026-06-11 | Pfeiffenberger Brent · President and CEO | Common Stock | F — Payment of exercise price or tax by delivering securities | −13,849 | SEC filing |
| 2026-06-05 | Pfeiffenberger Brent · President and CEO | Common Stock | F — Payment of exercise price or tax by delivering securities | −463 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2022-08-09 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −364,800 | SEC filing |
| 2022-01-31 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −178,996 | SEC filing |
| 2021-12-23 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −371,004 | SEC filing |
| 2021-06-17 | Casdin Eli · Director | Option (right to buy) | D — Disposition to the issuer | +39,744 | SEC filing |
Showing 4 of 4 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.